The peptide also influences pain receptors and circadian rhythms
You should not expect zero hunger after taking the medication
The most clearly defined groups who may be considered in future include individuals with: Metabolic dysfunction-associated steatotic liver disease (MASLD) particularly those with concurrent obesity, type 2 diabetes, or metabolic syndrome Metabolic dysfunction-associated steatohepatitis (MASH) the progressive inflammatory subtype associated with fibrosis and risk of cirrhosis Obesity with elevated liver enzymes (ALT/AST) where hepatic steatosis has been confirmed on imaging Type 2 diabetes with evidence of hepatic fat accumulation , where current glucose-lowering therapies have not adequately addressed liver disease Patients with significant hepatic fibrosis (stage F2 or above) represent a group with particularly high unmet need, as there are currently no licensed pharmacological treatments specifically approved for MASH in the UK
The STEP trials, published in the New England Journal of Medicine, showed participants taking semaglutide lost an average of 15% of body weight over 68 weeks
I was on contraceptive pills for 6 months to treat the PCOS & during that time, I didnt have any itching
When semaglutide therapy leads to weight loss, especially loss of visceral fat, the body's hormonal environment naturally shifts toward healthier cortisol patterns
